20 States May Legislate "Right to Try" This Year

Some 20 states could have new right to try laws on the books by this time next year, though time will tell what kind of impact they'll have for patients or drug makers

House "Cures" Proposal Faces Tough Road Ahead

The "discussion draft" for legislation to speed "21st Century Cures" to patients emerged very quietly on Capitol Hill this week. Jill Wechsler reports.

FDA Encourages Supplements for Oncology Drug

FDA's Office of Hematology and Oncology Products (OHOP) is testing a treamlined review process that could be much faster and less costly for certain therapies. Jill Wechsler reports.

2015: Blockbuster Year for M&A in Asia

The healthcare landscape in Asia-Pacific is expected to continue grow strongly in 2015, according to a report by Frost & Sullivan.

VC Optimism to China: Leading Biologics Company Raises $100m C Round

2014 was a banner year for investment in biotech, and there is little sign of decline. With an unprecedented $100m Series C round of financing, Innovent has demonstrated this optimism extends as far as China.

Shire CEO – Almost Ideal Timing for NPS Deal

Fresh off Shire’s announcement to purchase NPS, CEO Dr. Flemming Ornskov sat down with PharmExec in San Francisco during the JP Morgan Healthcare Conference.

Orphan Drug Prices Face Increased Scrutiny

With the FDA approving an all-time record number of orphan drugs during 2014, the pricing of these treatments is set to come under increased scrutiny.

Europe’s New Competition Commissioner: What Does it Mean for Pharma?

Brussels correspondent Reflector asks, what attitude will the new EC for competition, Margrethe Vestager, adopt to the pharmaceutical industry?

Top Tweets from JP Morgan

As we wrap up the week in San Francisco, here’s PharmExec's brief rundown of some of the top tweets of the week from JP Morgan and Biotech Showcase.

Institute of Medicine Maps Out Clinical Trial Data Sharing Program

Investigators and sponsors of clinical trials will have to make more detailed data available following study completion, according to a new report from an Institute of Medicine (IOM) expert panel.